Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

2.7K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.7K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.9K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.9K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.0K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential medical applicability of N-β-Ala and N-His dipeptidomimetics against breast cancer: short in vitro and in silico screening.

Scientific reports·2026
Same author

Decreased potential for lymphatic vessel generation is a hallmark of early diagnosed arterial hypertension and can be reversed by treatment with angiotensin converting enzyme inhibitors.

Scientific reports·2026
Same author

Reduced TIGIT Expression on T Cells Links Hyperglycemia to Immune Dysregulation in Type 1 Diabetes.

Cells·2026
Same author

Antiproliferative Activity of the New Analogues of Acridine/Acridone With Oligopeptide Derivatives and Molecular Docking With EGFR and Src Kinase.

Journal of peptide science : an official publication of the European Peptide Society·2025
Same author

Safety and efficacy of the therapy with CD4 + CD25highCD127-T regulatory cells: When paediatric patient becomes adult.

Diabetes, obesity & metabolism·2025
Same author

New analogs of 5-substituted-2(1<i>H</i>)-pyridone containing of natural amino acids as potential drugs in idiopathic pulmonary fibrosis. Investigation <i>in silico</i> and preliminary <i>in vitro</i>.

Acta biochimica Polonica·2025

Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

1.2K

[Adenosine, its analogues and conjugates].

Monika Samsel1, Krystyna Dzierzbicka1, Piotr Trzonkowski2

  • 1Politechnika Gdańska, Katedra Chemii Organicznej, Wydział Chemiczny.

Postepy Higieny I Medycyny Doswiadczalnej (Online)
|January 1, 2014
PubMed
Summary
This summary is machine-generated.

Novel adenosine analogues and conjugates are being developed to improve drug delivery and expand therapeutic applications beyond antiarrhythmic uses. These compounds show promise for treating immune diseases and other conditions.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

10.3K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.0K

Related Experiment Videos

Last Updated: May 4, 2026

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
04:17

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies

Published on: September 27, 2024

1.2K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

10.3K
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.0K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Adenosine is an endogenous purine nucleoside crucial for numerous biochemical processes.
  • It mediates its effects via four adenosine receptors (A1, A2A, A2B, A3) present in various physiological systems.
  • Current clinical use of adenosine is limited by its short blood half-life, particularly for its antiarrhythmic properties.

Purpose of the Study:

  • To explore novel adenosine analogues and conjugates with enhanced pharmacokinetic profiles.
  • To investigate the potential biological activities of these modified adenosine compounds.
  • To identify new therapeutic applications for adenosine derivatives.

Main Methods:

  • Synthesis of novel adenosine analogues and conjugates.
  • Preclinical and clinical evaluation of synthesized compounds.
  • Pharmacokinetic and pharmacodynamic studies of adenosine derivatives.

Main Results:

  • Adenosine analogues and conjugates exhibit improved pharmacokinetic properties compared to native adenosine.
  • Synthesized compounds demonstrate a wide range of biological activities, including antiarrhythmic, antinociceptive, antidiabetic, antiphlogistic, and antiviral effects.
  • These novel compounds show potential in modulating immune responses and treating immune-related diseases.

Conclusions:

  • Adenosine analogues and conjugates represent a promising area for drug development.
  • These compounds offer potential therapeutic benefits for various conditions, including cardiovascular diseases and immune disorders.
  • Further research into adenosine derivatives may lead to new treatment strategies.